The challenge of managing dyslipidemia in People Living with HIV (PLWHIV) is driven by
the high prevalence of Human Immunodeficiency (HIV) and can be due to various coexisting …

Human immunodeficiency virus (HIV) is a chronic disease associated with dyslipidemia and
insulin resistance. In addition, the administration of combination antiretroviral therapy is …

Dyslipidemia and lipid management in HIV-infected patients : Current Opinion in Endocrinology,
Diabetes and Obesity Dyslipidemia and lipid management in HIV-infected patients : Current …

Dyslipidemia is a common problem affecting a large proportion of patients infected with the
human immunodeficiency virus (HIV). Antiretroviral therapy (ART), particularly with certain …

Since the introduction of HAART, there was a remarkably change in the natural history of
HIV disease, leading to a notable extension of life expectancy, although prolonged …

Antiretroviral therapy has dramatically increased survival for HIV-infected individuals. Asthis
population lives longer, coronary heart disease has become an important comorbid …

Background Dyslipidaemia is a common metabolic condition occurring in people with HIV
(PWH), whether treated or untreated with antiretroviral therapy (ART). As people live longer …

Since the discovery and development of antiretroviral therapy (ART), HIV has become a
chronic disease with patients living longer lives and to ages where co‐morbidities, such as …

Dyslipidemias are more common in the patient population with human immunodeficiency
virus (HIV). Combination antiretroviral therapy (ART) has dramatically reduced HIV …

HIV-infected patients have metabolic abnormalities that put them at increased risk of
cardiovascular disease (CVD), including abnormalities associated with HIV infection itself …